Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Hemodynamic forces prevent myxomatous valve disease in mice through KLF2/4 signaling
Jesse A. Pace, … , Giovanni Ferrari, Mark L. Kahn
Jesse A. Pace, … , Giovanni Ferrari, Mark L. Kahn
Published June 16, 2025
Citation Information: J Clin Invest. 2025;135(12):e186593. https://doi.org/10.1172/JCI186593.
View: Text | PDF
Research Article Cardiology Vascular biology

Hemodynamic forces prevent myxomatous valve disease in mice through KLF2/4 signaling

  • Text
  • PDF
Abstract

Myxomatous valve disease (MVD) is the most common form of cardiac valve disease in the developed world. A small fraction of MVD is syndromic and arises in association with matrix protein defects such as those in Marfan syndrome, but most MVD is acquired later in life through an undefined pathogenesis. The KLF2/4 transcription factors mediate endothelial fluid shear responses, including those required to create cardiac valves during embryonic development. Here we test the role of hemodynamic shear forces and downstream endothelial KLF2/4 in mature cardiac valves. We find that loss of hemodynamic forces in heterotopically transplanted hearts or genetic deletion of KLF2/4 in cardiac valve endothelium confers valve cell proliferation and matrix deposition associated with valve thickening, findings also observed in mice expressing the mutant fibrillin-1 protein known to cause human MVD. Transcriptomic and histologic analysis reveals increased monocyte recruitment and TGF-β signaling in both fibrillin-1–mutant valves and valves lacking hemodynamic forces or endothelial KLF2/4 function, but only loss of TGF-β/SMAD signaling rescued myxomatous changes. We observed reduced KLF2/4 expression and augmented SMAD signaling in human MVD. These studies identify hemodynamic activation of endothelial KLF2/4 as an environmental homeostatic regulator of cardiac valves and suggest that non-syndromic MVD may arise in association with disturbed blood flow across the aging valve.

Authors

Jesse A. Pace, Lauren M. Goddard, Courtney C. Hong, Liqing Wang, Jisheng Yang, Mei Chen, Yitian Xu, Martin H. Dominguez, Siqi Gao, Xiaowen Chen, Patricia Mericko-Ishizuka, Can Tan, Tsutomu Kume, Wenbao Yu, Kai Tan, Wayne W. Hancock, Giovanni Ferrari, Mark L. Kahn

×

Figure 1

Hemodynamic forces control KLF2/4 expression in adult valve endothelial cells.

Options: View larger image (or click on image) Download as PowerPoint
Hemodynamic forces control KLF2/4 expression in adult valve endothelial ...
(A) Immunostaining for KLF4 (left) or in situ hybridization for Klf2 mRNA (right) costained with the endothelial marker CD31 and DAPI in mitral valve of adult mouse. Scale bars: 50 μm. (B) Schematic of unloaded and loaded heterotopic heart transplant (HHT) model in which the recipient abdominal aorta (R-AbA) is anastomosed to the donor ascending aorta (AA). The pulmonary artery (PA) of the donor heart is anastomosed to the recipient inferior vena cava (R-IVC) to allow for venous drainage of the donor heart. CS, coronary sinus; LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle. (C) TUNEL staining in mitral valve and myocardium of control and donor hearts 4 days after transplant. Scale bars: 50 μm. (D) H&E staining of myocardium at 4 days after HHT. Scale bars: 50 μm. (E) Quantitative PCR measurement of Klf2 and Klf4 mRNA expression using isolated mitral valve tissue from control and unloaded HHT hearts. ****P < 0.0001, by unpaired t tests. (F) In situ hybridization for Klf2 mRNA costained with CD31 and DAPI in mitral valves of control, loaded HHT, and unloaded HHT hearts 4 days after transplant was performed using RNAscope. Scale bars: 50 μm. (G) Quantification of Klf2 percentage area stained in F. *P < 0.05, **P < 0.01, ****P < 0.0001, by 2-way ANOVA with Tukey’s multiple-comparison tests. (H) Immunostaining for KLF4, ERG, and DAPI in mitral valves of control, loaded HHT, and unloaded HHT hearts 4 days after transplant. Scale bars: 50 μm. (I) Quantification of immunostaining in H. The percentage of valve endothelial cells (VECs), based on ERG expression, that are KLF4+ is shown. *P < 0.05, ***P < 0.001, by 2-way ANOVA with Tukey’s multiple-comparison tests. (J) In situ hybridization for Klf4 mRNA costained with DAPI in mitral valves of control, loaded HHT, and unloaded HHT hearts 4 days after transplant was performed using RNAscope. Scale bars: 50 μm. (K) Quantification of Klf4 percentage area stained in J. *P < 0.05, by 2-way ANOVA with Tukey’s multiple-comparison tests.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts